OCA
KNSA icon

Octagon Capital Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Octagon Capital Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-295,238
Closed -$5.22M – 34
2020
Q4 		$5.22M Buy
+295,238
New +$5.19M 1.81% 18

Other funds holding KNSA

HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Octagon Capital Advisors's KNSA Position: Q1 2021 in Review

Octagon Capital Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q1 2021, closing a stake of 295,238 shares — an estimated $5.22M sold.

Octagon Capital Advisors first reported a position in KNSA in Q4 2020 and held it in 1 quarter. The position peaked at $5.22M in Q4 2020. 105 funds tracked by Wall St. Rank hold KNSA as of Q1 2021.

  • Octagon Capital Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 295,238 Kiniksa Pharmaceuticals shares in Q1 2021, an estimated $5.22M.
  • Octagon Capital Advisors first reported a position in Kiniksa Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Octagon Capital Advisors's Kiniksa Pharmaceuticals position peaked at $5.22M in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2021.

Based on Octagon Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.